Physician profile
Andy N Orta
NPI 1285014845
$9,212.16
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,965 · 2020: $1,390 · 2021: $1,808 · 2024: $49.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rock Medical Orthopedics, INC. | $3,788.15 | 2019-2021 | |
| Integra Lifesciences Corporation | $2,042.85 | 2019-2021 | |
| Medical Device Business Services, INC. | $1,300.80 | 2019 | |
| Horizon Therapeutics Plc | $518.86 | 2019-2021 | |
| Stryker Corporation | $407.94 | 2019-2021 | |
| Smith+Nephew, INC. | $329.01 | 2019-2021 | |
| Melinta Therapeutics, LLC | $172.23 | 2019 | |
| Medtronic Vascular, INC. | $140.11 | 2019 | |
| Polarityte, INC. | $134.23 | 2020 | |
| In2bones USA, LLC | $81.29 | 2019 | |
| Paratek Pharmaceuticals, INC. | $43.97 | 2020-2021 | |
| Depuy Synthes Sales INC. | $42.14 | 2021-2024 | Na |
| Bioventus LLC | $40.86 | 2020-2021 | |
| Organogenesis INC. | $35.84 | 2020 | |
| Aroa Biosurgery Incorporated | $34.07 | 2019-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $29.66 | 2020 | |
| Merck Sharp & Dohme LLC | $28.91 | 2019 | |
| Novum Pharma, LLC | $24.17 | 2019 | |
| Convatec INC. | $17.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Orta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.